The National Institute for Health and Care Excellence (NICE) has also issued an evidence summary describing four RCTs in adults who were overweight or obese (BMI > 27kg/m2) with a variety of weight-related co-morbidities including dyslipidaemia, hypertension, type 2 diabets, and obstructive sleep apnoea. All of these studies compared liraglutide 3mg daily with placebo, and all participants also received lifestyle interventions for weight loss.